[Parosteal sarcoma of the radius in the course of etretinate therapy].
Vilon. P P; Fiche. M M; Maugars. Y Y; Ducloux. J M JM; Carlier. N N; Poirier. P P; Forest. M M; Prost. A A
Key Findings
- A parosteal osteosarcoma appeared in the right radius after a cumulative etretinate dose of 73 g.
- Previous reports linked etretinate to benign bone growths, not malignant tumors.
- The authors cannot rule out a causal relationship, but acknowledge the possibility of coincidence.
Practical Outcomes
- For self‑experimenters, this case suggests caution with long‑term, high‑dose etretinate use and highlights the need for regular bone health monitoring. It offers no actionable guidance for the peptide vilon or any protocol improvements.
Summary
A patient who took a lot of the drug etretinate over many years developed a rare bone cancer in the forearm. While earlier cases of bone growth from etretinate were harmless, this tumor might be related to the drug, but it could also just be a coincidence.
Abstract
A parosteal osteosarcoma of the right radius has developed in a patient treated for a long time by etretinate (total dose: 73 g). If brachial ossifications have been reported to etretinate in 2 cases, they were benign tumours; so coincidence is possible in our case. Nevertheless, a relation between the tumour and the treatment cannot be excluded and justify the report of this observation.
Study Information
pubmed
1991
1991-11-30T00:00:00.000Z